BCR and acute lymphoblastic leukemia: Moreover, in the TKI era, where HSCT is no longer indicated in many patients with BCR-ABL1 ALL [6], accurate determination of post-treatment MRD is critical to identify patients with sub-optimal TKI response, where HSCT may still offer the best chance of cure.